Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the fiscal quarter ended March 31, 2017.

Financial Highlights:

  • Cash and equivalents of $23.4 million at March 31, 2017, compared to $9.2 million at September 30, 2016.
  • During the first six months of fiscal year 2017, Anavex used $3.9 million in cash to fund operations, after receipt of $2.1 million in research and development incentive income.
  • Operating expenses of approximately $3.6 million compared to approximately $2.2 million for the comparative quarter.  This increase was a result of increased spending on research and development and clinical preparatory activities.
  • Net loss for the quarter of approximately $1.5 million, or $0.04 per share, compared to a net loss of approximately $2.0 million, or $0.06 per share for the comparative quarter.

“We are continuing 2017 with a stronger balance sheet than the previous quarter and a strengthened corporate team,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We are on track to initiate placebo-controlled efficacy and safety trials this year in Alzheimer’s and Parkinson’s disease as well as Rett syndrome, for which ANAVEX 2-73 was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA).”

Corporate Highlights

  • May 1, 2017 – Anavex announced the appointment of Emmanuel O. Fadiran, RPh, PhD, as Senior Vice President of Regulatory Affairs. Dr. Fadiran has 24 years of regulatory experience within the U.S. Food and Drug Administration (FDA), having held leadership positions at the FDA’s Center for Drug Evaluation and Research (CDER).
  • April 3, 2017 – Anavex announced the presentation of new mechanism of action data related to ANAVEX compounds targeting the sigma-1 receptor at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2017).- Preclinical data was presented indicating that in addition to reducing oxidative stress, ANAVEX 2-73, ANAVEX 3-71 and ANAVEX 1-41 demonstrate protective effects of the mitochondrial enzyme complexes I and IV during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.- Additional data was presented for ANAVEX 3-71 indicating that during pathological conditions, ANAVEX 3-71 demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.  In neurodegenerative diseases such as Alzheimer’s and Parkinson’s, synaptogenesis is believed to be impaired.
  • February 13, 2017 – Anavex announced the appointment of Peter Donhauser, D.O. to its Board of Directors.  Mr. Donhauser has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000.

The financial information for the three and six months ended March 31, 2017 should be read in conjunction with the Company’s condensed consolidated interim financial statements, which will appear on EDGAR and will be available on the Anavex website at www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com and connect with the company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

 
ANAVEX LIFE SCIENCES CORP.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
     
     
  March 31, September 30,
ASSETS   2017     2016  
Current    
Cash $ 23,351,567   $ 9,186,814  
Sales Tax Recoverable   60,636     79,347  
Prepaid expenses and deposits   141,989     180,124  
Total current assets   23,554,192     9,446,285  
Deposits   52,396     52,396  
Total assets $ 23,606,588   $ 9,498,681  
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current    
Accounts payable and accrued liabilities $ 2,033,692   $ 3,119,993  
Deferred grant income   86,205     70,532  
Total liabilities   2,119,897     3,190,525  
Common stock   41,377     36,169  
Additional paid-in capital   104,159,213     84,290,140  
Accumulated deficit   (82,713,899 )   (78,018,153 )
Total stockholders' equity   21,486,691     6,308,156  
Total liabilities and stockholders' equity $ 23,606,588   $ 9,498,681  
     
ANAVEX LIFE SCIENCES CORP.
CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited)
     
    2017     2016  
Operating Expenses    
General and administrative $ 1,116,014   $ 1,089,641  
Research and development   2,492,933     1,090,527  
Total operating expenses     3,608,947       2,180,168  
     
Operating Loss     (3,608,947 )     (2,180,168 )
Other income (expenses)    
Grant income   16,684     26,879  
Research and development incentive income   2,022,902     -  
Interest income, net   18,147     2,064  
Financing related charges and adjustments   -     151,330  
Foreign exchange gain (loss)   11,722     (30,906 )
Total other income (expenses)     2,069,455       149,367  
Net loss before income taxes   (1,539,492 )   (2,030,801 )
Income tax expense - current   (9,595 )   -  
Net loss $   (1,549,087 ) $   (2,030,801 )
     
Net loss per Share    
Basic $ (0.04 ) $ (0.06 )
Diluted $ (0.04 ) $ (0.06 )
     
Weighted Average Number of Shares Outstanding  
Basic   41,159,707     35,214,793  
Diluted   41,159,707     35,214,793  
     
ANAVEX LIFE SCIENCES CORP.
CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
SIX MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited)
     
    2017     2016  
Operating Expenses    
General and administrative $ 2,242,198   $ 3,982,746  
Research and development   4,535,423     2,729,856  
Total operating expenses     6,777,621        6,712,602  
     
Operating Loss     (6,777,621 )     (6,712,602 )
Other income (expenses)    
Grant income   51,970     65,934  
Research and development incentive income   2,022,902     571,093  
Interest income, net   21,802     4,206  
Financing related charges and adjustments   -     150,235  
Foreign exchange gain (loss)   25,804     (46,561 )
Total other income     2,122,478       744,907  
Net loss before income taxes   (4,655,143 )   (5,967,695 )
Income tax expense - current   (40,603 )   (17,615 )
Net loss $   (4,695,746 ) $   (5,985,310 )
     
Net loss per Share    
Basic $ (0.12 ) $ (0.17 )
Diluted $ (0.12 ) $ (0.17 )
     
Weighted Average Number of Shares Outstanding  
Basic   39,761,612     34,589,957  
Diluted   39,761,612     34,589,957  
     

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:  info@anavex.com

Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com

Media:
Dennis Dobson, Jr.
Dobson Media Group
203-258-0159
dennisdobsonjr@dobsonmediagroup.com

Social Media:
Bill Douglass
Gotham Communications 
646-504-0890
bill@gothamcomm.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Anavex Life Sciences Charts.